Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at stubborn leukemia

NCT ID NCT04230265

Terminated Disease control Sponsor: AvenCell Europe GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new therapy for patients with acute myeloid leukemia (AML) that had returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack cancer cells carrying a specific marker (CD123). The study aimed to find a safe dose and check for side effects in 32 adults. The trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
genetically modified T-cells (UniCAR02-T) combined with a targeting protein (TM123)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia (AML) that has come back or not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) trial that was terminated, so results are limited. The approach is complex and may cause serious side effects like immune reactions. It is not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

  • Erasmus University Medical Center

    Rotterdam, Gelderland, 3015, Netherlands

  • Klinikum der Universität München

    Munich, Bavaria, 81377, Germany

  • Philipps-Universität Marburg

    Marburg, Hesse, 35032, Germany

  • Uniklinik RWTH Aachen

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Universitair Medisch Centrum Groningen

    Groningen, GZ, 9713, Netherlands

  • Universitätsklinikum Dresden

    Dresden, Saxony, 01307, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Saxony, 04103, Germany

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.